Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Published loading...Updated

Alzheimer's among elderly more widespread than previously thought, new study shows

A study using a simple blood test found 11% of people over 70 meet criteria for antibody treatments that can slow early Alzheimer's disease progression.

  • Researchers at King's College London analysed 11,486 Trondelag Health Study blood samples and found around 11% of participants over 70 meet eligibility for monoclonal antibody treatments.
  • Using a blood biomarker test, researchers found Alzheimer's disease neuropathological changes rise sharply with age, from fewer than 8% in ages 65-69 to 65.2% in those over 90.
  • In participants over 70, 10% had pre-clinical Alzheimer's, while ADNC was present in 60 in dementia cases and 32.6 in mild cognitive impairment, the study shows.
  • Health services face challenges as lecanemab and donanemab, licensed but excluded by the spending watchdog, carry risks and require NHS preparation for specialist diagnostic tests not yet available.
  • More than 130 drugs in development aim to expand Alzheimer’s treatments, but experts advise caution and explore blood-based biomarkers for GP and primary care use.
Insights by Ground AI

7 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources lean Right
60% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

kcl.ac.uk broke the news in on Wednesday, December 17, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal